Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.
Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about the safety of the clinical trial.” Brazilian newspaper O Globo reported that the volunteer had been given a placebo and not the trial vaccine, citing unnamed sources.
Anvisa provided no further details, citing medical confidentiality of those involved in trials.
AstraZeneca declined immediate comment.
The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said the volunteer was Brazilian without revealing where the person lived.
AstraZeneca shares fell 1.7 per cent.